Cellyan Biotechnology Co., Ltd
HKPD
Last
$0.11
Day
+11.1%
1y
-92.3%
5y
-96.4%
52w
-94.1%
SPY YTD
+13.3%
XLV
+8.1%
Earnings
—
EMA 21
0.13
EMA 50
0.21
EMA 200
0.53
20d high
-19.6%
5y high
-97.3%
5y range
0th
Positions held
Your positionsHKPD isn't in your positions.
Add it to see shares, cost, and P&L here.
Score
-12
Hold
avoid
Signal
Sell
Target
$0.12
Stop
$0.09
Stop distance
19.6%
Target vs last
+7.1%
Fundamentals
| Market cap | $4.97M | Enterprise value | $3.41M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 0.25 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | -31.7% | Earnings growth | — | Gross margin | 10.3% | Operating margin | -19.3% |
| Profit margin | -8.5% | ROE | -15.6% | ROA | -5.6% | Debt / equity | 0.13 |
| Current ratio | 3.86 | Free cash flow | -$6.51M | Analyst recommendation | none | Mean target | — |
| 52w high | $1.72 | 52w low | $0.10 |
Quarterly
No data yet.
Yearly (6y)
| 2026 | 2025 | 2024 | 2023 | |
|---|---|---|---|---|
| Revenue | $13.4M | $20.3M | $16.7M | $12.6M |
| Op margin | -7.5% | 1.0% | 10.0% | 8.6% |
| Net income | -$1.1M | -$0.0M | $1.3M | $1.0M |
| Gross margin | 10.3% | 11.9% | 21.3% | 21.8% |
| Gross profit | $1.4M | $2.4M | $3.6M | $2.7M |
| Operating income | -$1.0M | $0.2M | $1.7M | $1.1M |
Headline scan
Headline risk — review
• [CRITICAL · listing] Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
News
2026-09-10 · BC-Most Active Stocks
2026-09-01 · BC-Most Active Stocks
2026-07-17 · Top Premarket Decliners
2026-07-16 · Cellyan Biotechnology Gets 180-Day Nasdaq Grace Period on Bid-Price Rule
2026-07-16 · Cellyan Biotechnology Co., Ltd Receives Nasdaq Notice of Additional Compliance Grace Period
Price (daily)
Full chart · RSI · MACD · patternsHKPD · daily-17.4% over 13 sessions
Close EMA21 EMA50 EMA200